These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers. Evans WE; Relling MV Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245 [TBL] [Abstract][Full Text] [Related]
6. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Smith CA; Gough AC; Leigh PN; Summers BA; Harding AE; Maraganore DM; Sturman SG; Schapira AH; Williams AC Lancet; 1992 Jun; 339(8806):1375-7. PubMed ID: 1350805 [TBL] [Abstract][Full Text] [Related]
7. Genotyping human polymorphic arylamine N-acetyltransferase: identification of new slow allotypic variants. Hickman D; Risch A; Camilleri JP; Sim E Pharmacogenetics; 1992 Oct; 2(5):217-26. PubMed ID: 1306121 [TBL] [Abstract][Full Text] [Related]
8. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. Aklillu E; Persson I; Bertilsson L; Johansson I; Rodrigues F; Ingelman-Sundberg M J Pharmacol Exp Ther; 1996 Jul; 278(1):441-6. PubMed ID: 8764380 [TBL] [Abstract][Full Text] [Related]
9. Debrisoquine hydroxylase gene polymorphism frequencies in patients with amyotrophic lateral sclerosis. Siddons MA; Pickering-Brown SM; Mann DM; Owen F; Cooper PN Neurosci Lett; 1996 Apr; 208(1):65-8. PubMed ID: 8731176 [TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population. Bozina N; Granić P; Lalić Z; Tramisak I; Lovrić M; Stavljenić-Rukavina A Croat Med J; 2003 Aug; 44(4):425-8. PubMed ID: 12950145 [TBL] [Abstract][Full Text] [Related]
13. N-acetyltransferase polymorphism. Comparison of phenotype and genotype in humans. Hickman D; Sim E Biochem Pharmacol; 1991 Aug; 42(5):1007-14. PubMed ID: 1872889 [TBL] [Abstract][Full Text] [Related]
14. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes. Longuemaux S; Deloménie C; Gallou C; Méjean A; Vincent-Viry M; Bouvier R; Droz D; Krishnamoorthy R; Galteau MM; Junien C; Béroud C; Dupret JM Cancer Res; 1999 Jun; 59(12):2903-8. PubMed ID: 10383153 [TBL] [Abstract][Full Text] [Related]
15. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. Nebert DW; McKinnon RA; Puga A DNA Cell Biol; 1996 Apr; 15(4):273-80. PubMed ID: 8639263 [TBL] [Abstract][Full Text] [Related]
16. CYP2D6 allelic frequencies in young-onset Parkinson's disease. Sandy MS; Armstrong M; Tanner CM; Daly AK; Di Monte DA; Langston JW; Idle JR Neurology; 1996 Jul; 47(1):225-30. PubMed ID: 8710083 [TBL] [Abstract][Full Text] [Related]
17. Mutant debrisoquine hydroxylation genes in Parkinson's disease. Armstrong M; Daly AK; Cholerton S; Bateman DN; Idle JR Lancet; 1992 Apr; 339(8800):1017-8. PubMed ID: 1349052 [TBL] [Abstract][Full Text] [Related]
18. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. Dahl ML; Johansson I; Bertilsson L; Ingelman-Sundberg M; Sjöqvist F J Pharmacol Exp Ther; 1995 Jul; 274(1):516-20. PubMed ID: 7616439 [TBL] [Abstract][Full Text] [Related]